>STARTSEITE

PBR Nachrichten

PBR (Pharmaceutical Business Review) ist ein Onlineportal mit News zur Pharma- und Biotechnologiebranche. Die Redaktion berichtet über neue Medikamente und deren Zulassungsverfahren, sowie über geschäftliche Entwicklungen von Pharmaunternehmen.
 
20.08.19 - 13:03
Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic asthma (PBR)
 
Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020. The post Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic ast...
20.08.19 - 10:16
FDA grants fast track status to Moderna’s Zika vaccine (PBR)
 
At present, the mRNA-1893 vaccine is being assessed in a phase 1 study to prevent Zika virus infection in healthy adults. The mRNA-1893 included an mRNA sequence that The post FDA grants fast track status to Moderna’s Zika vaccine appeared fir...
20.08.19 - 09:52
Angel-funded Siamab completes £166m exit with large commercial-stage biopharma (PBR)
 
Under the terms of the agreement, Siamab will receive a multimillion-dollar initial payment and is eligible to receive additional payments when specific milestones are achieved. No additional terms The post Angel-funded Siamab completes £166m exit w...
19.08.19 - 13:04
AbbVie receives FDA approval of RINVOQ for moderate to severe rheumatoid arthritis (PBR)
 
RINVOQ is expected to be available in the U.S. in late August 2019. The FDA approval of RINVOQ is supported by data from the SELECT program, one of The post AbbVie receives FDA approval of RINVOQ for moderate to severe rheumatoid arthritis appeared ...
19.08.19 - 13:04
Xynomic Research Institute successfully designs series of potent RET kinase inhibitors (PBR)
 
Rearranged during transfection (RET) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and survival. RET fusions are implicated in several cancers including The post Xynomic Research Institute s...
19.08.19 - 10:51
Celgene gets FDA approval for myelofibrosis treatment Inrebic (PBR)
 
Inrebic is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is a The post Celgene gets FDA approval for myelofibrosis treatment Inrebic app...
16.08.19 - 10:51
European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis (PBR)
 
"We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis The post European Medicines Agency validates marketing application for Filgo...
16.08.19 - 10:29
GeneCentric Therapeutics acquires Select ImmunoGenomics (PBR)
 
The acquisition provides the combined company with a comprehensive, integrated set of RNA-based solutions to enhance drug development by identifying the right patients for oncology drugs, improving response The post GeneCentric Therapeutics acquires...
16.08.19 - 09:05
Roche gets FDA nod for Rozlytrek to treat ROS1-positive NSCLC (PBR)
 
The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic The post Roche gets FDA nod for Rozlytrek to treat ROS1-positive NSCLC ap...
15.08.19 - 03:51
Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial (PBR)
 
The late-stage study called PAOLA-1 evaluated Lynparza plus bevacizumab in the first line maintenance setting in comparison to bevacizumab alone in women with advanced ovarian cancer, irrespective of The post Lynparza plus bevacizumab meets primary ...
14.08.19 - 13:04
Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial (PBR)
 
The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as The post Lilly announces superiority of Taltz versus TREMFYA in IXOR...
14.08.19 - 11:15
Landos Biopharma completes £49.7m series B financing (PBR)
 
The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University The post Landos Biopharma completes £49.7m ...
14.08.19 - 10:51
Boehringer Ingelheim, MD Anderson to jointly advance new cancer therapies (PBR)
 
In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves. The post Boehringer Ingelheim, MD Anderson to jointly advance new...
14.08.19 - 10:15
Janssen gets EC approval for two new indications of Imbruvica (PBR)
 
The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the The post Janssen gets EC approval for two new indications of Imbr...
13.08.19 - 13:04
Kedrion Biopharma announces enrollment of first patient in CARES10 trial (PBR)
 
CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10 percent intravenous immunoglobulin in the treatment of The post Kedrion Biopharma announces ...
13.08.19 - 12:51
Novartis′ Sandoz to appeal US district court ruling on biosimilar Erelzi (PBR)
 
The United States District Court of New Jersey gave ruling against Sandoz over the validity of the two patents that describe and claim Enbrel and the methods for The post Novartis' Sandoz to appeal US district court ruling on biosimilar Erelzi appe...
13.08.19 - 12:38
Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares (PBR)
 
BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company's common stock. According to the terms of the Proposal, The post Eidos Therapeutics confirms receipt o...
13.08.19 - 10:39
Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m (PBR)
 
As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around The post Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m appea...
12.08.19 - 13:27
Ascletis opens Clinical Development Shanghai Center (PBR)
 
Ascletis’ Clinical Development Shanghai Center is at the heart of Shanghai, located at Jing’an Kerry Centre near Nanjing West Road. The opening ceremony was held on Aug 11, The post Ascletis opens Clinical Development Shanghai Center app...
12.08.19 - 12:52
Neoleukin Therapeutics, Aquinox Pharmaceuticals complete merger transaction (PBR)
 
Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol "NLTX beginning on Monday, August 12, 2019, on the Nasdaq Global The post Neoleukin Therapeutics, Aquinox Pharmaceuticals complete...
>Zitat des Tages: Weine bezwingen den Geist und machen geneigt zur Entflammung: Bei einem vollen Pokal schwinden die Sorgen dahin. - Ovid
Partner:    >Tradegate Börse | >DB Xmarkets | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!